Promises to revolutionize how drug discovery teams guide their studies
Biologists at the University of California, San Diego have developed a revolutionary new method for identifying and characterizing antibiotics, an advance that could lead to the discovery of new antibiotics to treat antibiotic resistant bacteria.
The researchers, who published their findings in this week’s early online edition of the journal Proceedings of the National Academy of Sciences, made their discovery by developing a way to perform the equivalent of an autopsy on bacterial cells.
“This will provide a powerful new tool for identifying compounds that kill bacteria and determining how they work,” said Joseph Pogliano, a professor of biology at UC San Diego who headed the research team. “Some bacteria have evolved resistance to every known class of antibiotic and, when these multi-drug resistant bacteria cause an infection, they are nearly impossible to treat. There is an urgent need for new antibiotics capable of treating infections caused by antibiotic resistant bacteria.”
The Centers for Disease Control and Prevention issued an alarming report in March that antibiotic-resistant strains of Carbapenem-Resistant Enterobacteriaceae, or CRE, had been found to cause infections in patients in nearly 200 hospitals in the United States alone. Because no antibiotics on the market are effective at treating these infections, about one-half of patients die from CRE infections. These outbreaks are difficult to contain, and in a 2011 outbreak of Klebsiella pneumonia at the U.S. National Institutes of Health Clinical Center, the bacteria spread despite strict infection control procedures and was detected in drains and medical devices that had been subject to standard decontamination protocols.
“We are finally running out of the miracle drugs,” said Pogliano, who detailed the history: The antibiotic penicillin was first discovered in the late 1920s, and received widespread clinical use in the 1940s. However, bacteria quickly evolved resistance to penicillin, so new and better versions were developed. Since that time, a continuous race has been fought to identify new antibiotics in order to stay one step ahead of the evolving resistance. In the 2011 outbreak of Klebsiella, the bacteria evolved resistance even to colistin, a drug of last resort because of its severe side effects.
Over the last 25 years, the number of new antibiotics entering the clinic has drastically declined. At the same time, bacteria have continued to evolve resistance to all of the currently available drugs, creating the current critical situation. One of the main problems in identifying new antibiotics and bringing them to market is a lack of understanding how the molecules work.
“It’s easy to identify thousands of molecules capable of killing bacteria,” explained Kit Pogliano, a professor of biology and a co-author of the paper. “The hard part is picking out the winners from the losers, and choosing molecules that are the best candidates for drug development. One key piece of information needed for this choice is knowledge of how the drug works, but this is traditionally difficult information to obtain, usually requiring months of intensive work. We’ve applied 21st century methods that within just two hours provide this information, allowing more rapid prioritization of new molecules. This will open up the discovery pipeline, allowing us to more rapidly identify new molecules with potential to enter the clinic for treatment of multi-drug-resistant pathogens.”
One key to this new approach was the combination of microscopy and quantitative biology tools. “We had to develop all of the cell biology and quantitative biology methods for generating the data ourselves and that required a lot of work, but now that we have the method working, it is very exciting,” said Poochit Nonejuie, a graduate student in the Division of Biological Sciences and another co-author. “My chemistry colleagues can give me a new molecule in the morning, and by the afternoon I can tell them the likely cellular pathways that they target. It’s mind blowing how powerful the technology is.”
The UC San Diego biologists say their new method is not only game changing, but promises to revolutionize how drug discovery teams guide their studies. With previous methods, understanding how an antibiotic works requires many different biochemical assays to be performed, which requires a lot of time and relatively large quantities of the compound, which is almost always in short supply when it is first discovered.
“Our new method represents the first time that a single test can be performed and identify the likely mechanism of action for a new compound,” said Joseph Pogliano. He noted that postdoctoral fellow Anne Lamsa has miniaturized the method so that it requires just a few nanograms of each drug candidate, conserving molecules that are often available only in tiny quantities.
The Latest Bing News on:
Drug discovery
- Emerging Legal Terrain: IP Risks from AI's Role In Drug Discoveryon May 8, 2024 at 12:52 pm
This article explores the benefits and risks of AI-driven drug discovery from the legal perspective. Since the law governing IP rights in AI-driven drug discovery is still in its infant state, any future legal development is likely to have significant implications in many areas.
- Model Medicines' AI-Driven Drug Discovery Delivers Groundbreaking Advances in New Chemistry and Biologyon May 7, 2024 at 3:13 am
From helping doctors answer patient questions to making new drugs to cure hard diseases, there has been a lot of hype about how artificial intelligence (AI) is going to improve human health. In this excitement,
The Latest Google Headlines on:
Drug discovery
[google_news title=”” keyword=”Drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
New antibiotics
- Changes in pig farming in the 20th century spread antibiotic-resistant Salmonella around the world, finds studyon May 9, 2024 at 7:44 am
Historical changes in pig farming led to the global spread of Salmonella, resistant to antibiotics—a new international study led by researchers at the University of Warwick suggests. ...
- A mother's loss launches a global effort to fight antibiotic resistanceon May 9, 2024 at 5:33 am
In November 2017, days after her daughter Mallory Smith died from a drug-resistant infection at the age of 25, Diane Shader Smith typed a password into Mallory's laptop.
- A New Oral Antibiotic Is Available to Treat UTIson May 8, 2024 at 9:32 am
The FDA recently approved Pivya for uncomplicated UTIs. Pivya is an oral tablet that clears bacterial infections in the female bladder.
- DeepMind’s new AlphaFold 3 expands to DNA, RNA modelingon May 8, 2024 at 7:59 am
Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.
- Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectiveson May 8, 2024 at 1:00 am
2 About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of ...
- New plan to tackle antimicrobial resistance launchedon May 7, 2024 at 9:37 pm
A new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat, has been launched today.
- Automated alerts improved antibiotic prescribing for common infections: JAMA studieson May 3, 2024 at 12:15 pm
Pneumonia and urinary tract infections are the two most common infections requiring hospitalizations and major reasons for the overuse of broad-spectrum antibiotics. | Algorithm-driven alerts help ...
- FDA Approves New Antibiotic for Uncomplicated Urinary Tract Infectionson April 30, 2024 at 11:30 pm
The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs). The approval is for UTIs caused ...
- Swedish-led team discovers potential new class of antibiotics, hope for AMR fighton April 29, 2024 at 11:22 am
A new antibiotic against gram-negative bacteria hasn’t been developed since the 1970s. Now, a European research team led by Swedish scientists has discovered multi-drug-resistant bug-killing compounds ...
- FDA Approves New Antibiotic for Uncomplicated UTIson April 26, 2024 at 11:54 am
The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
The Latest Google Headlines on:
New antibiotics
[google_news title=”” keyword=”new antibiotics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]